It is great to have a partner like Indegene to help us focus on our strengths, while enabling us to get our innovation in the hands of the women who need this treatment.” At ConTIPI, we take pride in our Urogynecology expertise and innovation capabilities. “We have worked with Indegene to help us navigate the complex process from product innovation to patient adoption, and we are excited to continue to partner throughout this commercialization journey. Elan Ziv, CEO & Medical Director at ConTIPI Medical. “We are thrilled to introduce ProVate to women suffering from POP as this device will make it possible for them to take control of their own healthcare,” said Dr. The algorithm can learn from HCP interactions and adapts in real-time to deliver content that ultimately drives a change in the prescribing behavior. Using proprietary artificial intelligence (AI) and health care provider (HCP) data to expertly segment and target HCPs, Indegene helps clients deploy the most effective and efficient curated sales and marketing strategies. Indegene’s data-driven omnichannel marketing solution has been known to generate a greater impact than field sales representatives alone, resulting in better customer experiences at a fraction of the cost of the traditional model. Indegene will work with ConTIPI to drive revenue and ensure predictable cash outflow.
The device has a 510(k) clearance from the FDA for marketing in the USA and has been granted the CE mark for marketing in Europe.ĬonTIPI’s expanded agreement with Indegene includes several services across the commercialization process, including sales, PRMA (pricing, reimbursement and market access), medical affairs, medical communications, pharmacovigilance, regulatory, marketing and commercial operations support. This innovation empowers women to take control over their own treatment.
The current treatment methods include largely either invasive surgery with up to a 30% failure rate or the use of non-invasive pessaries which currently require a physician’s care to insert and remove and are associated with various adverse events.ĬonTIPI’s ProVate is a ready-to-use device that is inserted vaginally by the user thanks to an easy-to-use applicator, very similar to a menstrual tampon. Approximately 54 million American women over 20 years old suffer from POP 1. The US FDA states that POP occurs when the pelvic floor’s tissues and muscles can no longer support its organs which causes a drop or prolapse of the pelvic organs. and ISRAEL, (GLOBE NEWSWIRE) - Indegene, a digital-first, life sciences commercialization company announced today that it will be expanding its partnership with ConTIPI Medical Ltd, an innovator in the field of providing non-surgical and disposable solutions for women with various pelvic floor disfunctions, to bring a new device to the market.ĬonTIPI Medical’s mission is to help women suffering from Pelvic Organ Prolapse (POP).
0 kommentar(er)
